Somewhat Negative News Coverage Somewhat Unlikely to Affect Emergent Biosolutions (NYSE:EBS) Share Price

Media stories about Emergent Biosolutions (NYSE:EBS) have trended somewhat negative this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Emergent Biosolutions earned a media sentiment score of -0.01 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 44.6101219775266 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

EBS has been the topic of several research analyst reports. Zacks Investment Research cut Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Wells Fargo & Co reissued an “outperform” rating and set a $43.00 price objective (up from $41.00) on shares of Emergent Biosolutions in a research note on Saturday, September 30th.

Emergent Biosolutions (NYSE:EBS) traded up $0.56 on Friday, hitting $47.54. The stock had a trading volume of 208,146 shares, compared to its average volume of 305,994. The company has a market cap of $1,944.76, a price-to-earnings ratio of 24.86, a PEG ratio of 0.98 and a beta of 1.25. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38. Emergent Biosolutions has a 1-year low of $27.94 and a 1-year high of $49.25.

Emergent Biosolutions (NYSE:EBS) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.32. The business had revenue of $149.43 million during the quarter, compared to analysts’ expectations of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. Emergent Biosolutions’s revenue was up 4.6% compared to the same quarter last year. During the same quarter last year, the firm posted $0.56 earnings per share. equities research analysts expect that Emergent Biosolutions will post 1.66 EPS for the current fiscal year.

In related news, CEO Daniel Abdun-Nabi sold 31,508 shares of the stock in a transaction on Friday, November 3rd. The stock was sold at an average price of $42.77, for a total transaction of $1,347,597.16. Following the completion of the sale, the chief executive officer now directly owns 215,642 shares in the company, valued at $9,223,008.34. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Zsolt Harsanyi sold 7,000 shares of the stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total value of $297,290.00. Following the sale, the director now owns 37,077 shares of the company’s stock, valued at $1,574,660.19. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 206,329 shares of company stock valued at $8,892,362. 16.50% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: This report was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://ledgergazette.com/2018/01/13/emergent-biosolutions-ebs-receives-coverage-optimism-rating-of-0-01.html.

Emergent Biosolutions Company Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Insider Buying and Selling by Quarter for Emergent Biosolutions (NYSE:EBS)

Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply